Davion Healthcare Completes $25 Million Acquisition of Humaskan Intellectual Property
Davion Healthcare (DAVI) has finalized the acquisition of intellectual property from Humaskan, specifically targeting two medical technologies: WoundSkan and the Spektra Lateral Flow Test. The total transaction value is set at $25 million, which will be paid to the four existing shareholders of Humaskan. The deal includes an initial payment component of $2.5 million as part of the structured acquisition. This move is intended to expand Davion Healthcare's technological portfolio within the medical device and diagnostic sectors.
Tickers: $DAVI
Topics: Acquisition Intellectual Property Medical Technology